Evidence map›Paper›PMID 39992560›Full record

ReviewJournal of gastrointestinal cancer2025

Trends in the Global Incidence of Pancreatic Cancer and a Brief Review of its Histologic and Molecular Subtypes.

Premila Devi Leiphrakpam, Sanjib Chowdhury, Michelle Zhang, Varnica Bajaj, Mashaal Dhir, Chandrakanth Are

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Ellagic Acid Enhances RSL3-Induced Ferroptosis by Inhibiting the Nrf2/HO-1 Signaling Pathway in Pancreatic Ductal Adenocarcinoma.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  6. Aporphine AlkaloidPharmaceuticals (Basel, Switzerland) · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Comparative In Vitro Cytotoxicity ofCurrent issues in molecular biology · 2026
    Article
  11. Article
  12. The CaThe Journal of biological chemistry · 2026
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Premila Devi LeiphrakpamGraduate Medical Education, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.ORCID http://orcid.org/0000-0002-2319-8844
Sanjib ChowdhuryDepartment of Surgery, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Michelle ZhangDepartment of Surgery, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Varnica BajajDepartment of Surgery, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Mashaal DhirDepartment of Surgery, SUNY Upstate Medical University, Syracuse, NY, USA.
Chandrakanth AreGraduate Medical Education, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA. care@unmc.edu.ORCID http://orcid.org/0000-0001-7822-8898

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global burden of pancreatic cancer has more than doubled in recent decades. It is now the sixth leading cause of cancer-related death worldwide, with an estimated 510,922 new cases and 467,409 deaths in 2022. The incidence of the disease continues to rise annually, with projections indicating a 95.4% increase in new cases by 2050, potentially reaching a total of 998,663 new cases globally. The overall five-year survival rate for pancreatic cancer is 10% worldwide, showing only a modest improvement compared to the past decade. The rising trends in the incidence rates are likely to continue as the global population ages and access to healthcare improves. The relatively low survival rate is primarily attributed to late-stage diagnoses and the lack of an effective screening method. Currently, population-based screening for asymptomatic individuals is not recommended, highlighting the importance of identifying and monitoring individuals at high risk for pancreatic cancer. Numerous studies have highlighted the differences in the molecular pathology of pancreatic cancer, underscoring the need for continued research to better understand these differences. The silent progression of the disease, poor prognosis, lack of screening options, and the necessity to improve our comprehension of its molecular characteristics emphasize the critical need for ongoing monitoring of disease trends at the population level. This review article analyses trends in the incidence of pancreatic cancer and its histological subtypes and provides an update on its molecular subtypes.

Indexed as

Pancreatic NeoplasmsEarly Detection of CancerGlobal HealthHumansIncidencePrognosisGlobal cancer burdenHistological subtypesIncidenceMolecular subtypesPancreatic cancer

Identifiers

PMID39992560

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.